<SEC-DOCUMENT>0001193125-24-177726.txt : 20240711
<SEC-HEADER>0001193125-24-177726.hdr.sgml : 20240711
<ACCEPTANCE-DATETIME>20240711161229
ACCESSION NUMBER:		0001193125-24-177726
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240709
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240711
DATE AS OF CHANGE:		20240711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEAYA Biosciences, Inc.
		CENTRAL INDEX KEY:			0001676725
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474268251
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38915
		FILM NUMBER:		241112183

	BUSINESS ADDRESS:	
		STREET 1:		7000 SHORELINE COURT, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-443-6209

	MAIL ADDRESS:	
		STREET 1:		7000 SHORELINE COURT, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ideaya Biosciences, Inc.
		DATE OF NAME CHANGE:	20160609
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d807091d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:idya="http://www.ideayabio.com/20240709" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-296">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-07-09_to_2024-07-09">0001676725</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="idya-20240709.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-07-09_to_2024-07-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-09</xbrli:startDate> <xbrli:endDate>2024-07-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-307">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt:datemonthdayyearen" id="ixv-308">July&#160;9, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-309">IDEAYA Biosciences, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:stateprovnameen" id="ixv-310">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-311">001-38915</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-312">47-4268251</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-313">7000 Shoreline Court</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-314">Suite 350</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-315">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:stateprovnameen" id="ixv-316">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-317">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-318">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-319">443-6209</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:boolballotbox" id="ixv-320">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:boolballotbox" id="ixv-321">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:boolballotbox" id="ixv-322">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:boolballotbox" id="ixv-323">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-324">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-325">IDYA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:exchnameen" id="ixv-326">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-07-09_to_2024-07-09" format="ixt-sec:boolballotbox" id="ixv-327">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Underwriting Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;9, 2024, IDEAYA Biosciences, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P.&#160;Morgan Securities LLC, Goldman Sachs&#160;&amp; Co. LLC, Jefferies LLC and RBC Capital Markets, LLC, as representatives (the &#8220;Representatives&#8221;) of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell 7,228,572 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), and, in lieu of Common Stock to certain investors, <span style="white-space:nowrap">pre-funded</span> warrants (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) to purchase 285,715 shares of Common Stock (the &#8220;Warrant Shares&#8221;) to the Underwriters (the &#8220;Offering&#8221;). The price to the public in the Offering is $35.00 per Share and $34.9999 per <span style="white-space:nowrap">Pre-Funded</span> Warrant, which is the price per share at which the Shares are being sold to the public in the Offering, minus the $0.0001 exercise price per <span style="white-space:nowrap">Pre-Funded</span> Warrant. Each <span style="white-space:nowrap">Pre-Funded</span> Warrant will be exercisable from the date of issuance until fully exercised, subject to an ownership limitation. Pursuant to the Underwriting Agreement, the Underwriters have agreed to purchase the Shares from the Company at a price of $32.90 per Share and the <span style="white-space:nowrap">Pre-Funded</span> Warrants from the Company at a price of $32.8999 per <span style="white-space:nowrap">Pre-Funded</span> Warrant. In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters the option, for 30 days, to purchase up to 1,127,142 additional shares of Common Stock at the public offering price (the &#8220;Underwriters&#8217; Option&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company&#8217;s automatically effective shelf registration statement on Form <span style="white-space:nowrap">S-3,</span> as amended (Registration <span style="white-space:nowrap">No.&#160;333-272936).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities. The Company and the Company&#8217;s directors and executive officers also agreed not to sell or transfer any Common Stock without first obtaining the written consent of the Representatives on behalf of the Underwriters, subject to certain exceptions as described in the prospectus supplement, for 60 days after the date of the Prospectus, as defined in the Underwriting Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;11, 2024, the Offering closed and the Company completed the sale and issuance of an aggregate of 8,355,714 shares of Common Stock, including the exercise in full of the Underwriters&#8217; Option, and <span style="white-space:nowrap">Pre-Funded</span> Warrants to purchase 285,715 Warrant Shares. The Company received net proceeds of approximately $283.8&#160;million, after deducting the Underwriters&#8217; discounts and commissions and estimated offering expenses payable by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and <span style="white-space:nowrap">lock-up</span> arrangements do not purport to be complete and are qualified in their entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant is attached as Exhibit 4.1 hereto and is incorporated herein by reference. The foregoing descriptions of the <span style="white-space:nowrap">Pre-Funded</span> Warrants do not purport to be complete and are qualified in their entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Latham&#160;&amp; Watkins LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d) Exhibits. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d807091dex11.htm">Underwriting Agreement, dated as of July&#160;9, 2024, among IDEAYA Biosciences, Inc. and J.P. Morgan Securities LLC, Goldman Sachs&#160;&amp; Co. LLC, Jefferies LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d807091dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d807091dex51.htm">Opinion of Latham&#160;&amp; Watkins LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d807091dex51.htm">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">IDEAYA BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: July&#160;11, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yujiro Hata</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Yujiro Hata</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d807091dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IDEAYA Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7,228,572 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 285,715 Shares of Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Underwriting Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July&nbsp;9, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RBC CAPITAL MARKETS, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o RBC Capital Markets, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brookfield Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Vesey Street, 8<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10281 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences,
Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representatives (the &#147;Representatives&#148;),
(i) an aggregate of 7,228,572 shares of common stock, par value $0.0001 per share (&#147;Common Stock&#148;), of the Company (the &#147;Underwritten Shares&#148;) and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to purchase
an aggregate of 285,715 shares </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Common Stock in the form attached hereto as Exhibit A (the &#147;Warrants&#148;). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional
1,127,142 shares of Common Stock of the Company (the &#147;Option Shares&#148;). The Underwritten Shares and the Warrants are herein referred to as the &#147;Underwritten Securities.&#148; The Underwritten Shares and the Option Shares are herein
referred to as the &#147;Shares.&#148; The Shares and the Warrants are herein referred to as the &#147;Securities.&#148; The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the &#147;Warrant Shares.&#148; The
shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares and the exercise of the Warrants are referred to herein as the &#147;Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Securities, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-272936),</FONT> including a prospectus, relating to certain securities, including shares of Common Stock and the Warrants, to be issued from time to time
by the Company (the &#147;Base Prospectus&#148;). Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the
registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means the Base Prospectus
included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information and the preliminary prospectus supplement thereto dated July&nbsp;9, 2024 relating to the Securities in the form filed with the Commission
pursuant to Rule 424(b) under the Securities Act, and the term &#147;Prospectus&#148; means the Base Prospectus and the final prospectus supplement in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the
Securities Act) in connection with confirmation of sales of the Securities. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#147;Rule 462 Registration Statement&#148;), then any
reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#147;Agreement&#148;) to the Registration Statement, the Preliminary
Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the
Registration Statement or the date of the Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the
Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the
&#147;Exchange Act&#148;), that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the
following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): the Preliminary Prospectus and each &#147;free writing prospectus&#148; (as defined pursuant to Rule 405 under the
Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 6:45 P.M., New York City time, on July&nbsp;9, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Purchase of the Securities</U>. (a)&nbsp;The Company agrees to issue and sell the Underwritten Securities to the several
Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a
price per Share of $32.90 (the &#147;Share Purchase Price&#148;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto, and to purchase from the Company the Warrants in
respect of the respective number of Warrants set forth opposite such Underwriter&#146;s name in Schedule 1 hereto at a price of $32.8999 per Warrant (the &#147;Warrant Purchase Price&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the
Share Purchase Price less an amount per Share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. If any Option Shares are to be purchased, the number of Option
Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter
in Schedule 1 hereto (or such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to
eliminate any fractional Shares as the Representatives in their sole discretion shall make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to
purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate
number of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be
earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice
shall be given at least two business days prior to the date and time of delivery specified therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The Company understands
that the Underwriters intend to make a public offering of the Securities, and initially to offer the Securities on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell
Securities to or through any affiliate of an Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Payment for the Securities shall be made by wire transfer in immediately available
funds to the account specified by the Company to the Representatives in the case of the Underwritten Securities, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 1600 El Camino Real, Menlo Park, California 94025 at 10:00 A.M., New York City
time, on July&nbsp;11, 2024, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on
the date and at the time and place specified by the Representatives in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Securities is referred to herein as
the &#147;Closing Date,&#148; and the time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Securities to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against
delivery to the Representatives for the respective accounts of the several Underwriters of the Securities to be purchased on the Closing Date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the
sale of such Securities duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. The Warrants shall be delivered to the Representatives
in definitive form, registered in such names and in such denominations as the Representatives shall request in writing not later than the Closing Date. The Warrants will be made available for inspection by the Representatives on the business day
prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company and the Representatives shall instruct purchasers of the Warrants
in the public offering to make payment for the Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase price of $34.9999 per Warrant, in lieu of payment by the
Underwriters for such Warrants, and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of the Company&#146;s obligation to deliver such Warrants to the Underwriters;
provided that, the underwriting discounts and commissions in respect of the Warrants, as calculated by subtracting the Price per Warrant set forth on Annex A hereto from the Warrant Purchase Price set forth in Section&nbsp;2(a) hereof, shall be
deducted and withheld from the amount otherwise payable by the Representatives to the Company for the Shares as set forth above in this Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any purchaser of the Warrants in the public offering fails to make payment to the Company for all or part of the Warrants
(the &#147;Failed Warrants&#148;) on the Closing Date, the Representatives may elect, by written notice to the Company and payment of the Share Purchase Price by wire transfer in immediately available funds to the account specified by the Company at
the location and time designated in this Section&nbsp;2(c) for the Closing Date, to receive shares of Common Stock at the Share Purchase Price in lieu of the Failed Warrants that were otherwise to have been delivered to the purchasers thereof under
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in
the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any
other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible
for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review
by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Representatives and the other Underwriters and
shall not be on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Representations and Warranties of the Company</U>. The Company represents and warrants
to each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Preliminary Prospectus</I>. No order preventing or suspending the use of the
Preliminary Prospectus has been issued by the Commission, and the Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and the Preliminary
Prospectus did not, at the time of filing thereof, contain any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in
writing by such Underwriter through the Representatives expressly for use in the Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable
Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the
Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Issuer Free Writing Prospectus</I>. Other than the Registration
Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication
by the Company or its agents and representatives, excluding a communication referred to in clause (i)&nbsp;below, an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the
Representatives. Each such Issuer Free Writing Prospectus complied, or will comply, in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to
the extent required thereby), and, when taken together with the Registration Statement, the Pricing Disclosure Package, all other Issuer Free Writing Prospectuses and the Preliminary Prospectus accompanying, or delivered prior to delivery of, or
filed prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or
omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Materials</I>. The Company (i)&nbsp;has not engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT>
Communication&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) of, or Rule 163B under, the Securities Act. The Company has not distributed or approved for distribution any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below). &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Registration Statement and Prospectus</I>. The Registration Statement is an &#147;automatic shelf registration
statement&#148; as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection of the Commission to the use of such registration statement or
any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for
that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
related to the offering of the Securities has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement
and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and
as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or omissions
made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus and any
amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Incorporated Documents</I>. The documents incorporated by reference in the Registration Statement, the Prospectus
and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state
a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or
the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>Financial Statements</I>. The financial statements (including the related notes thereto) of the Company included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present
fairly in all material respects the financial position of the Company as of the dates indicated and the results of its operations and the changes in its cash flows for the periods specified; such financial statements have been prepared in conformity
with generally accepted accounting principles in the United States (&#147;GAAP&#148;) applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited interim financial statements, which are subject to normal <FONT
STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement
present fairly in all material respects the information required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived
from the accounting records of the Company and presents fairly in all material respects the information shown thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>No Material Adverse Change</I>. Since the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options
and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of
the Company, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a
material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity or results of operations or prospects of the Company; (ii)&nbsp;the Company has not entered into any transaction or
agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direct or contingent, that is material to the Company; and (iii)&nbsp;the Company has not sustained any loss or
interference with its business that is material to the Company and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any
court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>Organization and Good Standing</I>. The Company has been duly organized and is validly existing and in good
standing under the laws of its jurisdiction of organization, is duly qualified to do business and is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of its businesses requires such qualification, and
has all power and authority necessary to own or hold its properties and to conduct the business in which it is engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the
aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company or on the performance by the Company of its obligations under this
Agreement (a &#147;Material Adverse Effect&#148;). The Company does not have any subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>Capitalization</I>. The Company has an authorized capitalization as set forth in the Registration Statement, the
Pricing Disclosure Package and the Prospectus under the heading &#147;Description of Capital Stock&#148;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by the Pricing Disclosure Package and the Prospectus,
there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company, or any contract, commitment,
agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in
all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<I>Stock Options</I>. With respect to the stock options (the &#147;Stock Options&#148;) granted pursuant to the
stock-based compensation plans of the Company (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable,
approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if
any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all applicable laws and regulatory rules or requirements, including the
rules of the Nasdaq Global Select Market (the &#147;Nasdaq Market&#148;) and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements
(including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<I>Due Authorization</I>. The Company has full right, power and authority to execute and deliver this Agreement and
to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and
validly taken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<I>Underwriting Agreement</I>. This Agreement has been duly authorized, executed and delivered by
the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<I>The Securities</I>. The Shares to be issued and sold by the Company hereunder have been duly
authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights. The Warrants have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and
binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
rights and remedies of creditors or by general equitable principles, and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Warrants in a number sufficient to meet the current exercise requirements; the Warrant Shares, when issued and delivered
upon exercise of the Warrants in accordance therewith, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, and are not subject to any preemptive rights or similar rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;<I>No Violation or
Default</I>. The Company is not (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both,
would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which
the Company is bound or to which any property or asset of the Company is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except,
in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&#8195;<I>No Conflicts</I>. The execution, delivery and performance by the Company of this Agreement and the Warrants, the
issuance and sale of the Securities and the Warrant Shares by the Company and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or
result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any
property, right or asset of the Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any property, right or asset of
the Company is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or (iii)&nbsp;result in the violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or
encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&#8195;<I>No Consents
Required</I>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this
Agreement, the issuance and sale by the Company of the Securities and the Warrant Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Securities under the Securities Act and such
consents, approvals, authorizations, orders and registrations or qualifications as have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
already been obtained or made or as may be required by the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;), the Nasdaq Market and under applicable state securities laws in
connection with the purchase and distribution of the Securities by the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&#8195;<I>Legal Proceedings</I>.
Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings
(&#147;Actions&#148;) pending to which the Company is or may reasonably be expected to become a party or to which any property of the Company is or may reasonably be expected to become the subject that, individually or in the aggregate, if
determined adversely to the Company, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others;
and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the
Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&#8195;<I>Independent Accountants</I>. PricewaterhouseCoopers LLP, who has certified certain financial statements of the
Company, is an independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the
Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&#8195;<I>Title to Real and Personal Property</I>. The Company has good and marketable title in fee
simple (in the case of real property) to, or has valid rights to lease or otherwise use, all items of real and personal property that are material to the business of the Company, in each case free and clear of all liens, encumbrances, claims and
defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&#8195;<I>Intellectual Property</I>. Except as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus (i)&nbsp;to the knowledge of the Company, the Company owns or has the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark
registrations, domain names and other source indicators, copyrights, copyright registrations, copyrightable works, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, proprietary or confidential information and all
other intellectual property and proprietary and similar rights and all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
goodwill associated with any of the foregoing (collectively, &#147;Intellectual Property&#148;) in each case necessary for the conduct of its business in the manner described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;to the knowledge of the Company, the conduct of the Company&#146;s business as described in the Registration Statement, Pricing Disclosure Package and Prospectus has not
infringed, misappropriated or otherwise violated, and does not and will not infringe, misappropriate or otherwise violate any Intellectual Property of any third party in any material respect; (iii)&nbsp;there is no pending or, to the knowledge of
the Company, threatened action, suit, proceeding or claim by any third party (x)&nbsp;challenging the Company&#146;s rights in or to, or alleging violation of any terms of, any of its owned or licensed Intellectual Property, (y)&nbsp;alleging that
the Company has infringed, misappropriated or otherwise violated the Intellectual Property Rights of any third party or (z)&nbsp;challenging the ownership, validity, scope or enforceability of any Intellectual Property owned by or licensed to the
Company, and in the case of (x), (y) and (z)&nbsp;the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; and (iv)&nbsp;to the knowledge of the Company, except as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, all Intellectual Property owned by or licensed to the Company is valid and enforceable, is owned free and clear of all liens, encumbrances, defects and other
restrictions by, or licensed or <FONT STYLE="white-space:nowrap">co-licensed</FONT> to, the Company, and no third party has infringed, misappropriated or otherwise violated any Intellectual Property owned by or exclusively or <FONT
STYLE="white-space:nowrap">co-exclusively</FONT> licensed to the Company. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company has at all times taken reasonable steps in
accordance with normal industry practice to maintain the confidentiality of all Intellectual Property, the value of which to the Company is contingent upon maintaining the confidentiality thereof, including the execution of appropriate nondisclosure
and confidentiality agreements, and, to the knowledge of the Company, no such Intellectual Property has been disclosed except pursuant to such agreements. All parties involved in the development of Intellectual Property for the Company have signed
agreements with the Company, pursuant to which the Company either (A)&nbsp;has obtained ownership of and is the exclusive owner of such Intellectual Property, or (B)&nbsp;has obtained a valid right to exploit such Intellectual Property, sufficient
for the conduct of its business as currently conducted or as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&#8195;<I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company, on the
one hand, and the directors, officers, stockholders, customers or suppliers or other affiliates of the Company, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is
not so described in such documents and in the Pricing Disclosure Package. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&#8195;<I>Investment Company Act</I>. The
Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to
register as an &#147;investment company&#148; or an entity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder
(collectively, the &#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&#8195;<I>Taxes</I>. The Company has filed all U.S. federal,
state, local and foreign tax returns required to be filed, and has paid all U.S. federal, state, local and foreign taxes required to be paid through the date hereof, except in each case, as would not be expected to result in a Material Adverse
Effect; and except as would not be expected to result in a Material Adverse Effect, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its properties or assets. The charges,
accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are, in conformity with GAAP, adequate to meet any assessments or
<FONT STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not finally determined, except to the extent of any inadequacies that would not result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&#8195;<I>Licenses and Permits</I>. The Company possesses all licenses,
<FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities
that are necessary for the ownership or lease of its properties or the conduct of its business as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, including, without limitation, from the U.S. Food
and Drug Administration (&#147;FDA&#148;), except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and the Company has not received notice of any revocation or modification of
any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit, approval, clearance or authorization or has any reason to believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate,
permit or authorization will not be renewed in the ordinary course, except where the occurrence of such an event, individually or in the aggregate, would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&#8195;<I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company exists or, to the
knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers, contractors or customers, except as would not
have a Material Adverse Effect. The Company is not party to any collective bargaining agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&#8195;<I>Certain
Environmental Matters</I>. (i)&nbsp;The Company (x)&nbsp;is in compliance with all, and has not violated any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees and orders relating to
pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y) has received and is in compliance with
all, and has not violated any, permits, licenses, certificates or other authorizations or approvals required of it under any Environmental Laws to conduct its business; and (z)&nbsp;has not received notice of any actual or potential liability of the
Company, or obligation of the Company, under or relating to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or any actual or potential violation of, any Environmental Laws by the Company, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or
wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the
Company, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;(x) there is no proceeding that is pending,
or that is known by the Company to be contemplated, against the Company under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of
$100,000 or more will be imposed, (y)&nbsp;the Company is not aware of any facts regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes,
pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;the Company does not anticipate material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&#8195;<I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the
Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under common control with the
Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code) would have any liability (each, a
&#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the
meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the
funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or
Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148;
within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market value of the assets of each Plan exceeds the
present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated
thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would
cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to
the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a
material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of
such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company&#146;s &#147;accumulated post-retirement benefit obligations&#148; (within
the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company&#146;s most recently completed fiscal year, except in each case with respect to the
events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&#8195;<I>Disclosure Controls</I>. The Company maintains an effective system of &#147;disclosure controls and
procedures&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15(e)</FONT> of the Exchange Act) that has been designed to comply with the applicable requirements of the Exchange Act and designed to ensure that information required
to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and procedures
designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out an evaluation of its disclosure controls
and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&#8195;<I>Accounting Controls</I>. The Company maintains systems of &#147;internal control over financial reporting&#148;
(as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) designed to comply with the applicable requirements of the Exchange Act and that have been designed by, or under the supervision of, its principal executive
and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP,
including internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines
applicable thereto. There are no material weaknesses in the Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies
and material weaknesses, if any, in the design or operation of internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial
information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&#8195;<I>Insurance</I>. The Company has insurance covering its properties, operations, personnel and businesses, including
business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the Company reasonably believes are adequate to protect the Company and
its business; and the Company (i)&nbsp;has not received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance and (ii)&nbsp;has no
reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&#8195;<I>Cybersecurity; Data Protection</I>. The information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases owned by the Company (collectively, &#147;IT Systems&#148;), to the knowledge of the Company, are adequate for, and operate and perform in all material respects as required in
connection with the operation of the business of the Company as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has implemented and maintained
commercially reasonable policies and procedures to maintain its material personal data (&#147;Personal Data&#148;) and confidential information and the integrity, continuous operation, redundancy and security of all IT Systems used in connection
with its business, and, to the knowledge of the Company, there have been no breaches, violations or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other
person. The Company is presently in material compliance with all applicable laws, statutes, judgments, orders, and regulations of any governmental or regulatory authority and, to the Company&#146;s knowledge, all internal policies and contractual
obligations, in each case relating to the privacy and security of IT Systems and Personal Data, including, but not limited to, to the extent applicable, the General Data Protection Regulation (EU) 2016/679 and the California Consumer Privacy Act.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&#8195;<I>No Unlawful Payments</I>. Neither the Company, nor any director, officer or employee of the Company nor, to
the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to
political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any
government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or
improper payment or benefit. The Company has instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&#8195;<I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company are and have been conducted at
all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions
where the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;Anti-Money Laundering
Laws&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company,
threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<I>No Conflicts with Sanctions Laws</I>. Neither the Company nor any of its directors, officers or
employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company is currently the subject or the target of any sanctions administered or enforced by the U.S. government
(including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or
&#147;blocked person&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the Company located, organized or resident in a
country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, the Crimea Region and the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Zaporizhzhia and
Kherson Regions of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered Region of Ukraine identified
pursuant to Executive Order 14065 (each, a &#147;Sanctioned Country&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to
any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund
or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor
or otherwise) of Sanctions. Since </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
incorporation, the Company has not knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was
the subject or the target of Sanctions or with any Sanctioned Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&#8195;<I>No Broker&#146;s Fees</I>. The
Company is not a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder&#146;s fee or like payment
in connection with the offering and sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&#8195;<I>No Registration Rights</I>. No person has the
right to require the Company to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities by the Company hereunder, other than those
rights that have been validly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&#8195;<I>No Stabilization</I>. Neither the Company, nor, to the Company&#146;s
knowledge, its affiliates have taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price
of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&#8195;<I>Margin Rules</I>. Neither the issuance, sale and delivery of the Securities by the
Company nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will not violate Regulation&nbsp;T, U or X of the Board of Governors of the
Federal Reserve System or any other regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&#8195;<I>Forward-Looking Statements</I>.
No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&#8195;<I>Statistical and Market Data</I>. Nothing has come to the attention of the Company that has caused the Company to
believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and
accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&#8195;<I>Clinical Trials</I>. The clinical and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials conducted by or on behalf of or sponsored by the Company, or in which the Company has participated, that are described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with standard
medical and scientific research standards and procedures and all applicable statutes, including the Federal Food, Drug, and Cosmetic Act, and all applicable rules and regulations of the FDA and other applicable regulatory authorities (including,
without limitation, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) (collectively, the &#147;Regulatory Authorities&#148;) and
current Good Clinical Practices and Good Laboratory Practices; the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies and tests are accurate and complete in all material
respects and fairly present the data derived from such trials; the Company has no knowledge of any other trials, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement, the
Pricing Disclosure Package or the Prospectus; the Company has operated at all times and is currently in compliance in all material respects with all applicable statutes, rules and regulations of the Regulatory Authorities; and the Company has not
received any written notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or threatening the termination, material modification or suspension of any clinical or <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, and, to the knowledge of the Company, there are no reasonable grounds for the same. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&#8195;<I>Regulatory Filings</I>. The Company has not failed to file with the applicable Regulatory Authorities any
material required filing, declaration, listing, registration, report or submission; all such filings, declarations, listings, registrations, reports or submissions were in material compliance with applicable laws when filed; and no material
deficiencies have been asserted by any applicable Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports or submissions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&#8195;<I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the Company&#146;s
directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;),
including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&#8195;<I>Status under
the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule
164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this
offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&#8195;<I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or
preferred stock issued or guaranteed by the Company that are rated by a &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Further Agreements of the Company</U>. The Company covenants and agrees with
each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Required Filings</I>. The Company will file the final Prospectus with the Commission
within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, and will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly
all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as
the delivery of a prospectus is required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the
Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. The Company will pay the registration fee for
this offering within the time period required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Delivery of Copies</I>. The Company will deliver, upon request and without charge, (i)&nbsp;to the
Representatives, four signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each
Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including
all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such
period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172
under the Securities Act) in connection with sales of the Securities by any Underwriter or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Amendments
or Supplements, Issuer Free Writing Prospectuses</I>. Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement,
the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare,
use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Notice to the Representatives</I>. The Company will advise the
Representatives promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective;
(iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or
any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the
Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of the Preliminary
Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or, to the knowledge of the Company,
threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing
Disclosure Package, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not misleading; (vii)&nbsp;of the receipt by the Company of any notice of objection of the
Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act and (viii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the
qualification of the Securities for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the
issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of the Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Securities and, if any such order is issued, will obtain as soon as possible the withdrawal
thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Ongoing Compliance</I>. (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or
development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will promptly notify the
Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus
(or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances
existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing Date or any Additional Closing Date, as the case may be, (i)&nbsp;any event or
development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law,
the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives
may designate, such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as
so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Blue Sky Compliance</I>. The Company will qualify the Securities for offer and sale under the securities or Blue
Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Securities; <U>provided</U>, that the Company shall not be required to
(i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction
or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>Earnings
Statement</I>. The Company will make generally available to its security holders and the Representatives as soon as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the
Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement;
<U>provided</U>, that the Company will be deemed to have furnished such earnings statements to its security holders and the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval
system (&#147;EDGAR&#148;) or any successor system, and satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>Clear Market</I>. For a period of 60 days after the date of the Prospectus (the &#147;Restricted Period&#148;),
the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of,
directly or indirectly, or submit to, or file with, the Commission a registration statement under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to undertake any of the foregoing,
or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above
is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives, other than (A)&nbsp;the Securities to be sold hereunder and the delivery of the Warrant Shares upon
exercise of the Warrants, (B)&nbsp;any shares of Stock or other securities of the Company issued upon the exercise, vesting or settlement of options or other awards granted under Company Stock Plans or other equity incentive plan or stock purchase
plan (collectively, &#147;Equity Plans&#148;) in effect on the date hereof and that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, under the terms of such plan, (C)&nbsp;any options and other awards
granted or issued under an Equity Plan in effect on the date hereof and described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, under the terms of such plan, (D)&nbsp;the filing by the Company of any registration
statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to an Equity Plan in effect on the date hereof and described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
(E)&nbsp;the issuance of securities by the Company in connection with mergers, acquisitions or commercial or strategic transactions, provided that the aggregate number of shares issued pursuant to this clause (E)&nbsp;does not exceed 5% of the
Company&#146;s securities outstanding immediately following the issuance and sale of the Securities pursuant hereto; <U>provided</U>, that the recipient of any such shares of Stock or securities issued pursuant to clauses (B)&nbsp;and (E) during the
Restricted Period shall enter into an agreement for the remainder of the Restricted Period substantially in the form of Exhibit B hereto, and (F)&nbsp;the issuance and delivery of shares of Stock pursuant to the exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants outstanding on the date of this Agreement and described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The Company may only be released from the foregoing
restrictions with the prior written consent of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>Use of Proceeds</I>. The Company will
apply the net proceeds from the sale of the Securities as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>No Stabilization</I>. The Company will not take, directly or indirectly, without giving effect to activities by
the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<I>Exchange Listing</I>. The Company will use its reasonable best efforts to list for quotation the Shares and the
Warrant Shares on the Nasdaq Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;<I>Reports</I>. During a period of three years from the date of this
Agreement, the Company will furnish to the Representatives, as soon as commercially reasonable after the date that they are available, copies of all reports or other communications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(financial or other) furnished to holders of the Securities or Warrant Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national
securities exchange or automatic quotation system; <U>provided</U>, the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR or any successor system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies
of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;<I>Filings</I>. The Company will file with the Commission such reports as may be required by Rule 463 under the
Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&#8195;<I>Shelf Renewal</I>. If immediately prior to the third anniversary (the &#147;Renewal
Deadline&#148;) of the initial effective date of the Registration Statement, any of the Securities remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a
new shelf registration statement relating to the Securities, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has
not already done so, file a new shelf registration statement relating to the Securities, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after
the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein
to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be.<I> </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&#8195;<I>Warrant Shares Reserved</I>. The Company shall, at all times while any Warrants are outstanding, reserve and keep
available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants, the number of Warrant Shares that are initially
issuable and deliverable upon the exercise of the then-outstanding Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Certain Agreements of the Underwriters</U>. Each
Underwriter hereby severally represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;It has not, and will not, use, authorize use of, refer
to or participate in the planning for use of, any &#147;free writing prospectus,&#148; as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not
incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities
Act) that was not included (including through incorporation by reference) in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or
Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;It has not and will not, without the prior written consent of the Company, use any free writing prospectus that
contains the final terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided</U>, that Underwriters may use a term sheet substantially in the form of Annex B hereto
without the consent of the Company; <U>provided further</U>, that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrent with, the first use of such
term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;It is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect
to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Conditions of Underwriters&#146; Obligations</U>. The obligation of each Underwriter to purchase the Underwritten Securities on
the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its respective covenants and other obligations hereunder and to the following additional
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Registration Compliance; No Stop Order</I>. No order suspending the effectiveness of the
Registration Statement shall be in effect, and no proceeding for such purpose pursuant to Rule 401(g)(2) or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer
Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with
Section&nbsp;4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Representations and Warranties</I><I><U>.</U></I> The representations and warranties of the Company contained
herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this
Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>No Material Adverse Change</I>. No event or condition of a type described in Section&nbsp;3(h) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or the Additional
Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Officers&#146; Certificate</I>. The Representatives shall have received on and as of the Closing Date or the
Additional Closing Date, as the case may be, a certificate of the chief financial officer or principal accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives
(i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations of the Company set forth in Sections 3(b) and
3(e) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part
to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Comfort Letters</I>. On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the
case may be, PricewaterhouseCoopers LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Representatives, in form and substance reasonably
satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information
contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a <FONT
STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Opinion of Intellectual Property Counsel for the Company</I>. Each of: Goodwin Procter LLP; Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.; Lathrop GPM LLP; and Marshall, Gerstein&nbsp;&amp; Borun LLP, intellectual property counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinions, dated
the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Representatives, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Company</I>.
Latham&nbsp;&amp; Watkins, LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date or the
Additional Closing Date, as the case may be, and addressed to the Representatives, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT>
Statement of Counsel for the Underwriters</I>. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement,
addressed to the Representatives, of Davis Polk&nbsp;&amp; Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as
they may reasonably request to enable them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>No Legal Impediment to Issuance and/or
Sale</I>. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional
Closing Date, as the case may be, prevent the issuance or sale of the Securities by the Company; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing
Date, as the case may be, prevent the issuance or sale of the Securities by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>Good Standing</I>.
The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company in its jurisdiction of organization and its good standing in such
other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;<I>Exchange Listing</I>. The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case
may be, and any Warrant Shares, when issued and delivered upon exercise as provided under the Warrants, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;<I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit B hereto, between you and the officers and directors of the Company relating to sales and certain other dispositions of shares of Stock
or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#8195;<I>PFO/PAO Certificate</I>. On the date of this Agreement and on the Closing Date or the Additional Closing Date, as
the case may be, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Representatives, of its principal financial officer or principal accounting officer with
respect to certain financial data contained in the Pricing Disclosure Package and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;<I>Additional Documents</I>. On or prior to the Closing Date or the Additional Closing Date, as the case may be, the
Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Indemnification of the Underwriters by the Company</I>. The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, employees, agents, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses,
claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out
of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Prospectus (or any
amendment or supplement thereto), the Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any
Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with
any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in subsection (b)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Indemnification of the Company</I>. Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of
the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for
use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any Pricing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter
consists of the following information in the Prospectus furnished on behalf of each Underwriter under the caption &#147;Underwriting&#148;: the concession figure appearing in the third paragraph under the caption &#147;Underwriting&#148; and the
information describing passive market making activities and stabilization contained in the first, fourth, fifth and seventh sentences in the thirteenth paragraph beginning with the words &#147;In connection with this offering&#148; and the
fourteenth paragraph beginning with the words &#147;The underwriters have advised us&#148; under the caption &#147;Underwriting&#148; relating to price stabilization, short positions and penalty bids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Notice and Procedures</I>. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or
demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall promptly notify the person
against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U>, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding
paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided, further,</U> that the failure to notify the Indemnifying
Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified Person and it
shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person)
to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable fees and expenses in such proceeding and shall pay the
reasonable fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of
such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to
the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named
parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in
addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control
persons of such Underwriter shall be designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be
designated in writing by the Company. The Indemnifying Person shall not be liable for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss
or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as
contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person
of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified
Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement
(x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not
include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Contribution</I>. If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an Indemnified Person
or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or
payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other,
from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also
the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from
the sale of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the
Securities. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Limitation on Liability</I>. The Company and the Underwriters agree that it would not be just and equitable if contribution
pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable
considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably
incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which
the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their respective purchase obligations hereunder and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies</I>. The remedies provided for in this Section&nbsp;7 paragraphs
(a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if
after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any
of the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or
(iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement,
the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase
the Securities that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the
Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Securities, then the
Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Securities on such terms. If other persons
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
become obligated or agree to purchase the Securities of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the
Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration
Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement,
the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Securities that a defaulting
Underwriter agreed but failed to purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;If, after giving effect to any arrangements for the purchase of the Securities of a
defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the Closing Date
or the Additional Closing Date, as the case may be, does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Securities to be purchased on such date, then the Company shall have the right to require each <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Securities that
such Underwriter agreed to purchase on such date) of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Securities to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with
respect to any Additional Closing Date, the obligation of the Underwriters to purchase Securities on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the
payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Payment of Expenses</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will
pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and
any taxes payable in that connection, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Shares to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriters, or in the case of the Warrants, to the purchaser thereof, pursuant to this Agreement; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act
of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof;
(iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the
Securities under the state or foreign securities or blue sky laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and reasonable expenses
of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with,
and clearance of the offering by, FINRA, provided that the aggregate amount payable by the Company pursuant to clauses (iv)&nbsp;and (vii) shall not exceed $25,000 (excluding filing fees); (viii) all expenses incurred by the Company in connection
with any &#147;road show&#148; presentation to potential investors (provided, however, that the Underwriters and the Company shall each pay 50% of the cost of chartering any aircraft to be used in connection with the road show by the Company and the
Underwriters); (ix) all expenses and application fees related to the listing of the Shares and the Warrant Shares on the Nasdaq Market; and (x)&nbsp;the costs of reproducing and distributing each of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;If (i)&nbsp;this Agreement is terminated pursuant to clause (ii)&nbsp;of Section&nbsp;9, (ii) the Company for any reason fails to
tender the Securities for delivery to the Underwriters, or in the case of the Warrants, to the purchaser thereof or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this Agreement, the Company agrees to
reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in
connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to
purchase the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be
binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to in Section&nbsp;7 hereof and the affiliates, employees and agent of each Underwriter referred to in Section&nbsp;7
hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any
Underwriter shall be deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Survival</U>. The respective indemnities,
rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered
pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or
the directors, officers, controlling persons, employees, agents or affiliates referred to in Section&nbsp;7 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except
where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to
be closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<I>Notices</I>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P.&nbsp;Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (facsimile: (212) <FONT
STYLE="white-space:nowrap">622-8358);</FONT> Attention: Equity Syndicate Desk; c/o Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282, Attention: Registration Department; c/o Jefferies LLC, 520 Madison Avenue, New York, NY
10022; Attention: General Counsel; and c/o RBC Capital Markets, LLC, 200 Vesey Street, 8<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York 10281, Attention: Equity Capital Markets (facsimile: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-428-6260).</FONT></FONT> Notices to the Company shall be given to it at IDEAYA Biosciences, Inc., 7000 Shoreline Court, Suite 350, South San Francisco, California 94608; Attention:
General Counsel and Chief Executive Officer, with a copy (which shall not constitute notice) to Latham&nbsp;&amp; Watkins LLP, 140 Scott Drive, Menlo Park, CA 94025; Attention: Mark V. Roeder (facsimile: (650)
<FONT STYLE="white-space:nowrap">463-2600);</FONT> email:&nbsp;mark.roeder@lw.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<I>Governing Law</I>. This Agreement and any
claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state
courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the
laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to
the jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<I>Waiver of Jury Trial</I>. Each of the parties
hereto hereby waives any right to trial by jury in any legal proceeding arising out of or relating to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;16(e): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>Counterparts</I>. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#8195;<I>Amendments or Waivers</I>. No amendment or waiver of any provision of this
Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>Headings</I>. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect
the meaning or interpretation of, this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IDEAYA Biosciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yujiro Hata</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Yujiro Hata</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RBC CAPITAL MARKETS, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benjamin Burdett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director, Head of Healthcare ECM</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Parisi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Daniel Parisi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Brinkman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Brinkman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RBC CAPITAL MARKETS, LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Hoffman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Hoffman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director, ECM</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,710,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,168,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,626,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,228,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a.<B> Pricing Disclosure Package</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b. <B>Pricing Information Provided by Underwriters</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Offering Price Per Share:&#8194;&#8195;$35.00 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Shares:&#8194;&#8195;7,228,572 Underwritten Shares plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:19%; font-size:10pt; font-family:Times New Roman">1,127,142 Option Shares </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and Commissions:&#8194;&#8195;$2.10 per Share </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Offering Price Per Warrant:&#8194;&#8195;$34.9999 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Warrants:&#8194;&#8195;285,715 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and Commissions:&#8194;&#8195;$2.10 per Warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IDEAYA Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IDEAYA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#8195;&#8195;&#8195;&#8195;] (subject to adjustment) </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. CS - [&#8195;&#8195;&#8195;&#8195;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original Issue Date: [&#9679;] [&#8195;&#8195;&#8195;], 2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#8195;&#8195;&#8195;&#8195;] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [&#8195;&#8195;&#8195;&#8195;] shares of common stock, $0.0001 par value per share (&#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the
&#147;<B>Warrant Shares</B>&#148;) at an exercise price equal to $0.0001 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;) upon surrender of this Warrant to Purchase Shares of
Common Stock (including any Warrants to Purchase Shares of Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue
Date</B>&#148;) and, subject to the following terms and conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with,
a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative meanings,
&#147;controlled by,&#148; &#147;controlling&#148; and &#147;under common control with&#148;) means, with respect to a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of such
Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant, or other similar
arrangement) or other comparable equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following requirements: (i)&nbsp;the issuer thereof is then subject to the
reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its filing of all required reports and other information under the
Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on
or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and
(iii)&nbsp;following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by
the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction, except to the extent that any such restriction (x)&nbsp;arises solely under federal or
state securities laws, rules or regulations, and (y)&nbsp;does not extend beyond six (6)&nbsp;months from the closing of such Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the shares of Common Stock are
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Registration
Statement</B>&#148; means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-272936),</FONT> that became effective on June&nbsp;26, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the shares of Common Stock are not listed
or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law
or other governmental action to close. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Transfer Agent</B>&#148; means Equiniti Trust Company, LLC, the Company&#146;s transfer agent
and registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>VWAP</B>&#148; means, for any date, the price determined
by the first of the following clauses that applies: (i)&nbsp;if the Common Stock is then listed or quoted on a national securities exchange or other trading market, the daily volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on the Principal Trading Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if the Common Stock is then listed or quoted for trading and
neither OTCQB nor OTCQX is the Principal Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (iii)&nbsp;if the Common Stock is not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &#147;Pink Sheets&#148; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per share of the Common Stock so reported, or (iv)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The
Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance
pursuant to the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144
promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall
include the initial Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the
purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of
Transfers</I>. Subject to compliance with all applicable securities laws and, if applicable, the rules of the Principal Trading Market, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase shares of Common Stock in substantially the form of this
Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in
respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this Section&nbsp;3. Until due presentment for registration of transfer, the Company
may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.
<I>Exercise and Duration of Warrants</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in
Section&nbsp;10 at any time and from time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the
Company (i)&nbsp;an exercise notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant
is being exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to Section&nbsp;10 below), and the date on which the last of such items is delivered to the Company (as determined in
accordance with the notice provisions hereof) is an &#147;<B>Exercise </B><B>Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice
shall have the same effect as cancellation of the original Warrant and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Upon
exercise of this Warrant, the Company shall promptly (but in no event later than three (3)&nbsp;Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not
participating in the Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;), issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#146;s share
register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so
designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the
date of delivery of the certificates evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) If by the close of the third (3rd) Trading Day after the
Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit the Holder&#146;s DTC account for
such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction, provided such purchases shall be made in a
commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT
STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall, within two (2)&nbsp;Trading Days after the Holder&#146;s request, in the Holder&#146;s sole discretion, either (i)&nbsp;pay cash to the Holder in an amount equal to the
Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#146;s obligation to deliver such Warrant Shares shall terminate, or
(ii)&nbsp;(A) pay in cash to the Holder the amount, if any, by which (1)&nbsp;the Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock purchased in the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> exceeds (2)&nbsp;the product of (x)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue, multiplied by (y)&nbsp;the price at which
the sell order giving rise to such purchase obligation was executed (assuming such sale was executed on commercially reasonable terms at prevailing market prices and, if the sale was executed in multiple transactions, the volume weighted average
price), and (B)&nbsp;at the option of the Holder, either (1)&nbsp;reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or
(2)&nbsp;deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The provisions of this Section&nbsp;5(b) shall be the only remedy
available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section&nbsp;5(a) and a <FONT STYLE="white-space:nowrap">Buy-In</FONT> occurs. Irrespective of
whether there is a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> no remedy shall be available, notwithstanding the requirements of Section&nbsp;5(a), unless and until the Company fails to deliver to the Holder the required number of Warrant Shares
by the close of the third Trading Day after the Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s
obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to
enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or
alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation
of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section&nbsp;5(b), nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and
delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties)
in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer
involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or
transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such
other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant
to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company
covenants that it will, at all times while this Warrant is issued and outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it
to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase
rights of persons other than the Holder (taking into account the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable
Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that
such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the shares of Common Stock may be listed.
The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the shares of Common Stock at any time while this Warrant is issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is issued and
outstanding, (i)&nbsp;pays a stock dividend on its shares of Common Stock or otherwise makes a distribution on any class of capital shares issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, as described in the Registration Statement, that is payable in shares of Common Stock, (ii) subdivides its issued and outstanding shares of Common Stock into a larger number of shares of Common Stock,
(iii)&nbsp;combines its issued and outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of capital shares any additional shares of Common Stock of the Company, then in each such
case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock issued and outstanding immediately before such event and the denominator of which shall be the number of shares of Common
Stock issued and outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record
date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall become effective immediately after
the effective date of such subdivision or combination. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is issued and outstanding,
distributes to all holders of shares of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of shares of Common Stock covered by the preceding paragraph), (iii) rights or
warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, &#147;<B>Distributed Property</B>&#148;), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of
stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled
to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is issued and outstanding (i)&nbsp;the Company effects any merger or consolidation of
the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting
power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction); or (v)&nbsp;the Company effects any reclassification of the shares
of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of
Common Stock covered by Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount
and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the
surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to
Section&nbsp;10 below or (ii)&nbsp;prior to, simultaneously with or promptly following the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the
obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall
similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of shares of Common Stock consists solely of
cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148; pursuant to Section&nbsp;10 below effective
immediately prior to and contingent upon the consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Number of Warrant Shares</U>. Simultaneously with any
adjustment to the Exercise Price pursuant to Section&nbsp;9 (including any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon
exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate
Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the shares of Common Stock then in effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest <FONT
STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Adjustments</U>. Upon the occurrence of
each adjustment pursuant to this Section&nbsp;9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such
adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#146;s transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is issued and outstanding, the Company (i)&nbsp;declares a dividend or any other distribution of
cash, securities or other property in respect of its shares of Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii)&nbsp;authorizes or
approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such
notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the
applicable record or effective date on which a Person would need to hold shares of Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein
shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is issued and outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits
stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof shall be deemed to
constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is
consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Payment of</I> <I>Cashless Exercise Price</I>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole
discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to
Section&nbsp;3(a)(9) of the Securities Act as determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be
issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the last VWAP immediately preceding the time of delivery of the Exercise Notice giving rise to the applicable &#147;cashless
exercise&#148;, as set forth in the applicable Exercise Notice (to clarify, the &#147;last VWAP&#148; will be the last VWAP as calculated over an entire Trading Day such that, in the event that this Warrant is exercised at a time that the Trading
Market is open, the prior Trading Day&#146;s VWAP shall be used in this calculation); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then
in effect on the Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the
Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally
issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set forth in
Section&nbsp;12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially
owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act (such as any other members of a
Section&nbsp;13(d) &#147;group&#148;) to exceed [4.99][9.99]% (the &#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting
power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of
the Exchange Act (such as any other members of a Section&nbsp;13(d) &#147;group&#148;) to exceed [4.99][9.99]% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this
Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any
other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic mail
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this
Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage
specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company.
For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act (such as any other members of a Section&nbsp;13(d) &#147;group&#148;) shall include the shares of Common Stock issuable upon the exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion
of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that
do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time shares of Common Stock, including without limitation any debt, preferred stock, right, option, warrant
or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock), is subject to a limitation on conversion or exercise analogous to the
limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the
Exchange Act (such as any other members of a Section&nbsp;13(d) &#147;group&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of
Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the last VWAP immediately
preceding the time of delivery of the applicable Exercise Notice) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other
communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is
delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via
confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon
actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7000 Shoreline Court, Suite 350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, California
94080 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with copies to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (650) <FONT STYLE="white-space:nowrap">328-4600</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mark V. Roeder </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT
STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such
other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any
corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a
Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, amalgamation, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of
Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon
the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to
perform its obligations under this Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may
be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction in which this Warrant is not automatically &#147;cashless
exercised&#148;. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person
other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT
AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED
HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of
the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any
respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable
provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IDEAYA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Yujiro Hata</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. <U>&#8195;&#8195;</U> (the &#147;Warrant&#148;) issued by IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> Warrant Shares pursuant to
the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash Exercise</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the
terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) By its delivery of this Exercise Notice, the
undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of
the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>&#8195;&#8195;&#8195;</U>, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN
SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RBC CAPITAL MARKETS, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o RBC Capital Markets, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brookfield Place </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Vesey Street, 8<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10281 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IDEAYA Biosciences, Inc. &#150; Public Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as Representatives of the several Underwriters, propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;), providing
for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock and/or <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants of the Company (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public
Offering of the Securities, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co.
LLC, Jefferies LLC and RBC Capital Markets, LLC, on behalf of the several Underwriters (the &#147;Representatives&#148;), the undersigned will not, subject to the exceptions set forth in this letter agreement (the &#147;Letter Agreement&#148;),
during the period beginning on the date of this Letter Agreement and ending on, but including, the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day after the date of the final prospectus supplement relating to the Public Offering (the
&#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of common stock, $0.0001 per share par value, of the Company (the &#147;Common Stock&#148;) or any securities convertible into or exercisable or exchangeable for Common Stock
(including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be
issued upon exercise of a stock option or warrant) (collectively, the &#147;Undersigned&#146;s Shares&#148;), or publicly disclose the intention to make any offer, sale, pledge or disposition, (2)&nbsp;enter into any swap or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such
other securities, in cash or otherwise or (3)&nbsp;make any demand for, or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, in each
case other than: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) any Securities to be sold by the undersigned pursuant to the Underwriting Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;transfers of the Undersigned&#146;s Shares as a bona fide gift or gifts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;transfers or dispositions of the Undersigned&#146;s Shares to any trust for the direct or indirect benefit of the undersigned or the
immediate family of the undersigned; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) transfers or dispositions of the Undersigned&#146;s Shares to any corporation, partnership,
limited liability company or other entity all of the beneficial ownership interests of which are held by the undersigned or the immediate family of the undersigned; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) transfers or dispositions of the Undersigned&#146;s Shares by will, other testamentary document or intestate succession to the legal
representative, heir, beneficiary or a member of the immediate family of the undersigned; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) if the undersigned is a corporation, partnership, limited liability company or other
entity, distributions of the Undersigned&#146;s Shares to partners, members or stockholders of the undersigned; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G) if the
undersigned is a corporation, partnership, limited liability company or other entity, transfers of the Undersigned&#146;s Shares to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the undersigned;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that in the case of any transfer or distribution pursuant to clause (B), (C), (D), (E), (F) or (G), each transferee, donee or distributee
shall execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and <U>provided further</U>, that in the case of any transfer, disposition or distribution pursuant to
clause (B), (C), (D), (E), (F) or (G), no filing by any party (donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be
made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above or a filing on Schedule 13D, 13F or 13G that is required to be filed during the
Restricted Period, or, in the case of (B)&nbsp;only, a filing on Form 4 during the Restricted Period, each of which shall clearly indicate in the footnotes thereto the nature and conditions of such transfer) and any such transfer or distribution
shall not involve a disposition for value. For purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. The undersigned now has, and, except as
contemplated by clause (A), (B), (C), (D), (E), (F), or (G)&nbsp;above, for the duration of this Letter Agreement will have, good and marketable title to the Undersigned&#146;s Shares, free and clear of all liens, encumbrances, and claims
whatsoever, other than any charitable pledge of the Undersigned&#146;s Shares that by its terms could not result in any transfer, disposition or distribution of such shares during the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions imposed by this Letter Agreement, the undersigned may, without the prior written consent of the
Representatives: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) exercise an option to purchase shares of Common Stock granted under any equity incentive plan, stock purchase plan
or other equity award plan (each, an &#147;Equity Plan&#148;), described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or filed as an exhibit to the Registration Statement, either
through cash or &#147;cashless&#148; exercise (the term &#147;cashless&#148; exercise being intended to mean the surrender of a portion of the option shares or previously owned shares to the Company to cover payment of the exercise price),
<U>provided</U> that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this Letter Agreement, and <U>provided further</U> that no filing under the Exchange Act or other public
announcement reporting a reduction in the aggregate beneficial ownership of the Undersigned&#146;s Shares shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than a
filing on Schedule 13D, 13F or 13G), and that any public filing or announcement relating to this clause (i)&nbsp;shall briefly note the applicable circumstances that cause this exception to this Letter Agreement to apply (provided, however, that for
the avoidance of doubt, this clause (i)&nbsp;shall not be construed to in any way limit or narrow the scope of clause (vi)&nbsp;of this paragraph below); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) establish a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Common Stock (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;), <U>provided</U> that such plan is approved by the Company and does not
provide for any transfers of Common Stock during the Restricted Period, and <U>provided further</U> that no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection therewith during the
Restricted Period except as required by law or regulation, provided that to the extent such filing under the Exchange Act or other public announcement is required by law or regulation, such filing or announcement shall include a statement to the
effect that no transfers may be made pursuant to such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan during the Restricted Period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) transfer or dispose of shares of Common Stock acquired in the Public Offering or on the open market following the Public Offering,
<U>provided</U> that no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than a filing on Schedule 13D, 13F
or 13G); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) transfer to the Company shares of Common Stock (A)&nbsp;pursuant to any contractual arrangement that provides the Company
with an option to repurchase such shares of Common Stock in connection with the termination of the undersigned&#146;s employment or other service relationship with the Company or (B)&nbsp;in connection with the vesting, settlement, or exercise of
outstanding restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and
remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant
to (x)&nbsp;an agreement or (y)&nbsp;equity awards granted under an Equity Plan, each such agreement or Equity Plan which is described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or
filed as an exhibit to the Registration Statement, and, <U>provided further</U> that any filing under Section&nbsp;16 of the Exchange Act with regard to (A)&nbsp;or (B) shall clearly indicate in the footnotes thereto that the filing relates to the
circumstances described in (A)&nbsp;or (B) above, as the case may be; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) transfer or dispose of Common Stock by operation of law
pursuant to a qualified domestic order or in connection with a divorce settlement or other court order, <U>provided</U> that the recipient of such shares of Common Stock shall execute and deliver to the Representatives a <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) sell, transfer or dispose of the
Undersigned&#146;s Shares pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan that is in effect as of the date hereof, provided that any public filing, report or announcement of any such sale or transfer shall disclose the nature of
such sale or transfer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, this Letter Agreement shall not restrict any sale, disposal or transfer of the
Undersigned&#146;s Shares to a bona fide third party pursuant to a tender offer for securities of the Company or any merger, consolidation or other business combination involving a Change of Control of the Company occurring after the settlement of
the Public Offering, that, in each case, has been approved by the board of directors of the Company; <U>provided</U> that all of the Undersigned&#146;s Shares subject to this Letter Agreement that are not so transferred, sold, tendered or otherwise
disposed of remain subject to this Letter Agreement; and <U>provided further</U>, that it shall be a condition of transfer, sale, tender or other disposition that if such tender offer or other transaction is not completed, any of the
Undersigned&#146;s Shares subject to this Letter Agreement shall remain subject to the restrictions herein. For the purposes of this paragraph, &#147;Change of Control&#148; means the consummation of any bona fide third party tender offer, merger,
consolidation or other similar transaction, the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company or its subsidiaries, becomes the beneficial owner
(as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of at least 100% of the total voting power of the voting share capital of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. This Letter Agreement may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly
and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not
provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial,
regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to the
undersigned in connection with the Public Offering, the Representatives and the other Underwriters are not making a recommendation to the undersigned to enter into this Letter Agreement or participate in the Public Offering, and nothing set forth in
such disclosures is intended to suggest that any Representative or any Underwriter is making such a recommendation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that if either the Representatives, on the one hand, or the
Company, on the other hand, informs the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, if the Underwriting Agreement does not become effective by July&nbsp;31, 2024, or if
the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, the undersigned shall be released from all
obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and
construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IF AN INDIVIDUAL:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IF AN ENTITY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8194;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8201;<I>(duly authorized signature)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(please print complete name of entity)</I></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:&#8194;<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8201;&#8195;<I>(please print full name)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8201;<I>(duly authorized signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#8194;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8201;&#8195;<I>(please print full name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8201;&#8195;<I>(please print full title)</I></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d807091dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IDEAYA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#8195;] (subject to adjustment) </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant No. CS&#151;[&#8195;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">Original Issue Date: [&#149;] [&#8195;], 2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [ ]
shares of common stock, $0.0001 par value per share (&#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an exercise price equal to
$0.0001 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;) upon surrender of this Warrant to Purchase Shares of Common Stock (including any Warrants to Purchase Shares of Common
Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;) and, subject to the following terms and conditions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are
used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative meanings, &#147;controlled by,&#148;
&#147;controlling&#148; and &#147;under common control with&#148;) means, with respect to a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through
ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant, or other similar arrangement) or other comparable
equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following requirements: (i)&nbsp;the issuer thereof is then subject to the
reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its filing of all required reports and other information under the
Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on
or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and
(iii)&nbsp;following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by
the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction, except to the extent that any such restriction (x)&nbsp;arises solely under federal or
state securities laws, rules or regulations, and (y)&nbsp;does not extend beyond six (6)&nbsp;months from the closing of such Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the shares of Common Stock are
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Registration
Statement</B>&#148; means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-272936),</FONT> that became effective on June&nbsp;26, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the shares of Common Stock are not listed
or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law
or other governmental action to close. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Transfer Agent</B>&#148; means Equiniti Trust Company, LLC, the Company&#146;s transfer agent
and registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>VWAP</B>&#148; means, for any date, the price determined
by the first of the following clauses that applies: (i)&nbsp;if the Common Stock is then listed or quoted on a national securities exchange or other trading market, the daily volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on the Principal Trading Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if the Common Stock is then listed or quoted for trading and
neither OTCQB nor OTCQX is the Principal Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (iii)&nbsp;if the Common Stock is not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &#147;Pink Sheets&#148; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per share of the Common Stock so reported, or (iv)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The
Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance
pursuant to the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144
promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall
include the initial Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the
purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of
Transfers</I>. Subject to compliance with all applicable securities laws and, if applicable, the rules of the Principal Trading Market, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase shares of Common Stock in substantially the form of this
Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in
respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this Section&nbsp;3. Until due presentment for registration of transfer, the Company
may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.
<I>Exercise and Duration of Warrants</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in
Section&nbsp;10 at any time and from time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the
Company (i)&nbsp;an exercise notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant
is being exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to Section&nbsp;10 below), and the date on which the last of such items is delivered to the Company (as determined in
accordance with the notice provisions hereof) is an &#147;<B>Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have
the same effect as cancellation of the original Warrant and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)
Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3)&nbsp;Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not
participating in the Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;), issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#146;s share
register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so
designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the
date of delivery of the certificates evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) If by the close of the third (3rd) Trading Day after the
Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit the Holder&#146;s DTC account for
such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction, provided such purchases shall be made in a
commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT
STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall, within two (2)&nbsp;Trading Days after the Holder&#146;s request, in the Holder&#146;s sole discretion, either (i)&nbsp;pay cash to the Holder in an amount equal to the
Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#146;s obligation to deliver such Warrant Shares shall terminate, or
(ii)&nbsp;(A) pay in cash to the Holder the amount, if any, by which (1)&nbsp;the Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock purchased in the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> exceeds (2)&nbsp;the product of (x)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue, multiplied by (y)&nbsp;the price at which
the sell order giving rise to such purchase obligation was executed (assuming such sale was executed on commercially reasonable terms at prevailing market prices and, if the sale was executed in multiple transactions, the volume weighted average
price), and (B)&nbsp;at the option of the Holder, either (1)&nbsp;reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or
(2)&nbsp;deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The provisions of this Section&nbsp;5(b) shall be the only remedy
available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section&nbsp;5(a) and a <FONT STYLE="white-space:nowrap">Buy-In</FONT> occurs. Irrespective of
whether there is a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> no remedy shall be available, notwithstanding the requirements of Section&nbsp;5(a), unless and until the Company fails to deliver to the Holder the required number of Warrant Shares
by the close of the third Trading Day after the Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s
obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to
enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or
alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation
of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section&nbsp;5(b), nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the
terms hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of certificates for shares of Common Stock upon
exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of
which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant
Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon
exercise hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued
in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s
obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times while this Warrant is
issued and outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into
account the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly
and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the shares of Common Stock may be listed. The Company further covenants that it will not,
without the prior written consent of the Holder, take any actions to increase the par value of the shares of Common Stock at any time while this Warrant is issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is issued and
outstanding, (i)&nbsp;pays a stock dividend on its shares of Common Stock or otherwise makes a distribution on any class of capital shares issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, as described in the Registration Statement, that is payable in shares of Common Stock, (ii) subdivides its issued and outstanding shares of Common Stock into a larger number of shares of Common Stock,
(iii)&nbsp;combines its issued and outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of capital shares any additional shares of Common Stock of the Company, then in each such
case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock issued and outstanding immediately before such event and the denominator of which shall be the number of shares of Common
Stock issued and outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record
date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall become effective immediately after
the effective date of such subdivision or combination. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is issued and outstanding,
distributes to all holders of shares of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of shares of Common Stock covered by the preceding paragraph), (iii) rights or
warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, &#147;<B>Distributed Property</B>&#148;), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of
stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled
to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is issued and outstanding (i)&nbsp;the Company effects any merger or consolidation of
the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting
power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction); or (v)&nbsp;the Company effects any reclassification of the shares
of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of
Common Stock covered by Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount
and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the
surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to
Section&nbsp;10 below or (ii)&nbsp;prior to, simultaneously with or promptly following the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the
obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall
similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of shares of Common Stock consists solely of
cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148; pursuant to Section&nbsp;10 below effective
immediately prior to and contingent upon the consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Number of Warrant Shares</U>. Simultaneously with any
adjustment to the Exercise Price pursuant to Section&nbsp;9 (including any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon
exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate
Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the shares of Common Stock then in effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest <FONT
STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Adjustments</U>. Upon the occurrence of
each adjustment pursuant to this Section&nbsp;9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such
adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#146;s transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is issued and outstanding, the Company (i)&nbsp;declares a dividend or any other distribution of
cash, securities or other property in respect of its shares of Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii)&nbsp;authorizes or
approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such
notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the
applicable record or effective date on which a Person would need to hold shares of Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein
shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is issued and outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits
stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof shall be deemed to
constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is
consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Payment of</I> <I>Cashless Exercise Price</I>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole
discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to
Section&nbsp;3(a)(9) of the Securities Act as determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be
issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the last VWAP immediately preceding the time of delivery of the Exercise Notice giving rise to the applicable &#147;cashless
exercise&#148;, as set forth in the applicable Exercise Notice (to clarify, the &#147;last VWAP&#148; will be the last VWAP as calculated over an entire Trading Day such that, in the event that this Warrant is exercised at a time that the Trading
Market is open, the prior Trading Day&#146;s VWAP shall be used in this calculation); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then
in effect on the Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the
Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally
issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set forth in
Section&nbsp;12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially
owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act (such as any other members of a
Section&nbsp;13(d) &#147;group&#148;) to exceed [4.99][9.99]% (the &#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting
power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of
the Exchange Act (such as any other members of a Section&nbsp;13(d) &#147;group&#148;) to exceed [4.99][9.99]% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this
Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any
other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic mail
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this
Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage
specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company.
For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act (such as any other members of a Section&nbsp;13(d) &#147;group&#148;) shall include the shares of Common Stock issuable upon the exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion
of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that
do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time shares of Common Stock, including without limitation any debt, preferred stock, right, option, warrant
or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock), is subject to a limitation on conversion or exercise analogous to the
limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the
Exchange Act (such as any other members of a Section&nbsp;13(d) &#147;group&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of
Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the last VWAP immediately
preceding the time of delivery of the applicable Exercise Notice) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other
communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is
delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via
confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon
actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7000 Shoreline Court, Suite 350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, California
94080 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with copies to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (650) <FONT STYLE="white-space:nowrap">328-4600</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mark V. Roeder </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT
STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such
other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any
corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a
Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, amalgamation, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of
Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon
the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to
perform its obligations under this Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may
be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction in which this Warrant is not automatically &#147;cashless
exercised&#148;. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person
other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT
AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED
HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of
the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any
respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable
provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IDEAYA BIOSCIENCES, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yujiro Hata</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. ___ (the &#147;Warrant&#148;) issued by IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cash Exercise</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the
terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) By its delivery of this Exercise Notice, the
undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of
the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Holder:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d807091dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park,
California 94025</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel:&nbsp;+1.650.328.4600&nbsp;Fax:&nbsp;+1.650.463.2600</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g807091g0711061605164.jpg" ALT="LOGO" STYLE="width:2.50556in;height:0.179861in;">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Austin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Century City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">July&nbsp;11, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tel Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington, D.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7000
Shoreline Court, Suite 350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, California 94080 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-272936</FONT> on Form <FONT
STYLE="white-space:nowrap">S-3;</FONT> Up to 8,355,714 Shares of Common Stock, par value $0.0001 per share and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 285,715 shares of Common Stock, $0.0001 par value per share
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection
with the proposed issuance of up to 8,355,714 shares of common stock of the Company, $0.0001 par value per share (the &#147;<B><I>Shares</I></B>&#148;), and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 285,715 shares of
Common Stock (the &#147;<B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I></B>&#148;). The Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are included in a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on June&nbsp;26, 2023 (Registration <FONT
STYLE="white-space:nowrap">No.&nbsp;333-272936)</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;), a base prospectus included in the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;) and a prospectus supplement dated
July&nbsp;9, 2024 (together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;), and an underwriting agreement dated July&nbsp;9, 2024, by and among J.P. Morgan Securities LLC, Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and RBC
Capital Markets, LLC, as representatives of the several underwriters named in the underwriting agreement, and the Company (the &#147;<B><I>Underwriting Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the
issue of the Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and Warrant Shares (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel,
we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual
matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>July 11, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g807091g0711061605645.jpg" ALT="LOGO" STYLE="width:1.73333in;height:0.116667in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as
of the date hereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. When the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the
name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement, the issue and sale of the Shares will have been duly
authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>In rendering the foregoing opinion, we have assumed that the
Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. When the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly issued by the Company against payment therefor in the circumstances contemplated by Underwriting Agreement, the issue and sale of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will have been duly authorized by all necessary corporate action of the Company, and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will be legally valid and binding
obligations of the Company, enforceable against the Company in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. When the shares of Common Stock initially
issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (the &#147;<B><I>Warrant Shares</I></B>&#148;) shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on
behalf of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant holders, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the issue of the Warrant Shares will have been duly authorized by all necessary corporate action of the Company, and the Warrant Shares will have been validly reserved by all necessary
corporate action of the Company, and the Warrant Shares will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the foregoing
opinions, we have assumed that (i)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL and (ii)&nbsp;upon the issue of any of the Warrant Shares, the total number of shares of
Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its Amended and Restated Certificate of Incorporation and by the board of directors of the Company in
connection with the offering contemplated by the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With your consent, we have assumed that the
status of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants as legally valid and binding obligations of the Company is not affected by any (i)&nbsp;breaches of, or defaults under, agreements or instruments, (ii)&nbsp;violations of
statutes, rules, regulations or court or governmental orders, or (iii)&nbsp;failures to obtain required consents, approvals or authorizations from, or make required registrations, declarations or filings with, governmental authorities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>July 11, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g807091g0711061605645.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinions are subject to: (i)&nbsp;the effect of bankruptcy, insolvency, reorganization,
preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii)&nbsp;(a) the effect of general principles of equity, whether considered in a proceeding in equity or at law
(including the possible unavailability of specific performance or injunctive relief), (b) concepts of materiality, reasonableness, good faith and fair dealing, and (c)&nbsp;the discretion of the court before which a proceeding is brought; and
(iii)&nbsp;the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to
public policy. We express no opinion as to (a)&nbsp;any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute a
penalty; (b)&nbsp;consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief; (c)&nbsp;any provision requiring the payment of attorneys&#146; fees, where such payment is contrary to law or public
policy; (d)&nbsp;other applicable exceptions; and (e)&nbsp;the severability, if invalid, of provisions to the foregoing effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to
the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated July&nbsp;9, 2024 and to the reference to our firm in the Prospectus under the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby
admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>idya-20240709.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 7/12/2024 12:10:29 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:idya="http://www.ideayabio.com/20240709"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.ideayabio.com/20240709"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="idya-20240709_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="idya-20240709_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>idya-20240709_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 7/12/2024 12:10:29 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>idya-20240709_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 7/12/2024 12:10:29 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="idya-20240709.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g807091g0711061605164.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g807091g0711061605164.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 .T# 2(  A$! Q$!_\0
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MH.A_Y$./_L&#_P!%5D?"S_D4#_U\O_):**7VEZ#_ .7%3_$OU/+M _Y+,_\
=U^O_ .A&OH>BBHP^S]3JSGXZ?^%!11170>.?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g807091g0711061605645.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g807091g0711061605645.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  + *0# 2(  A$! Q$!_\0
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)**M'/)W=S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140237439691616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001676725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IDEAYA Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4268251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Shoreline Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">443-6209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IDYA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVLCD& P$B4C+;_9RG(C3 'HF@!X#:,%=/JB@7###IF,E#T39WJ!F+XJA%M$
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( (Z!ZU@'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ CH'K6#P+&D3N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ CH'K6)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ".@>M8E1S;16X$  !"$0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ CH'K6)^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ".@>M8EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    " ".@>M8'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ CH'K6"0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ CH'K6&60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d807091d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d807091d8k.htm">d807091d8k.htm</File>
    <File>idya-20240709.xsd</File>
    <File>idya-20240709_lab.xml</File>
    <File>idya-20240709_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d807091d8k.htm": {
   "nsprefix": "idya",
   "nsuri": "http://www.ideayabio.com/20240709",
   "dts": {
    "inline": {
     "local": [
      "d807091d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "idya-20240709.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "idya-20240709_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "idya-20240709_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-07-09_to_2024-07-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d807091d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-07-09_to_2024-07-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d807091d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ideayabio.com//20240709/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-24-177726-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-177726-xbrl.zip
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M8J,\.7>MXAIV>9SB*.\"*8?="04%@<A ,90)$@CUB>\Q"X,FFW"7\, GH%)
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MX.A=4M^F_Y!/C@!'FO28P\#A^TSE%[9PU+S/\WB@EFNC9\M(?THLE?R'&;^
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MM_>X#^9S;.^O;CYT;PJ=JXN+L^M>MQ5_^)IS;(:Q-(5&U$?@I,5\T&(M\WG
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M14\]2@.OKJOI0,[7@=PL@$M"NCB00X<U9H$D])M!##"@6T$<SD*<.]T+(;5
M0U"\(N<"!@,A ?5KG5# >F& 6+5C]_.>2G1+HHVMG2""&!/<'S/S_![-DV #
M( 2<@P<!SHW9J.7K1BW&X?QFTCB-YB%SN(79L%.:MIEAZG@"V#\>4"08*WG@
M&+)XK!?V'7Q[CZN^Q0,P$'E;J0%I%&'4LHK\;RO5(II6]7BCC/]2A.0C;H-E
M@@2B&0O0(,6->L]8W4?Z3+EN(),/@Y\G8^Z&>NZ8P=B$20O\P=1B3X>_2+J8
M1'KZ!*!^0([Z+ 9+>00#*<8*9CNZB8UBA^^R(NBT.F00.LXTV0C(@1_V_\9
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MKB7SU>\NJAQ89\39 %RXN-+H2E<:;1(,G);T#Y6JWS!M_Q]02P,$%     @
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M42][.R+;/J+*16-(")/OQ1QL5JW:O ?\T)\73T '/_43>87<DYP-CRGA;R]
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M>E[]QSVRH8_4)CQNMP:P:H++ ,.LX#2"OP-ASL6/J2LBY$_K7%-[N.C(X-<
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M6UQYAZM_35>.\GQ8-%J8#([<1WT2,MFFBDLL,N.TO* 4KB5!#@8)R7BC2'O
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M(]W>3]BY(>]+A[,,[O 7H)KG>5!8+0I/?^UAH5]3URRJF X+7E+/=KCFIT$
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M/623_C?QFT3\7'OE4-'NLS_WD^/#HT??/_KA)Z]J8,)'59=%1IV_UG"9T1E
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M_<*:/:?IIE1#/JW..!G3>IWK3%I0FFH[3\EL\>58J1^0==2:)=O?>Q3<ORY
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ML4EJB#P:(0E2ZA!JK@2KR-J>S6/(<+4F8&>@4S;G:&E*4D<_&CJ"=5T6#2(
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MY7O UA+")[YSF6.![R,+3QKYS;HRB'8N#?M77)YKZI<&B4C],4ZUE#H=86M
MI)'W>;X:CWSR$GH(A&2\_[>:<[M,19%A4"6P==@!ZL(7%.M?ES+^C"0BG34%
M/X$!LQN7Y;ZKR0:5 _45<O?2K:)A^R)A@9>1CMU'PLCUY/S4T8]=X$<D"P)/
MTE69A.TDZ>].,$PW!/Z_/+#N27W[)DE]='P;"*P/#0+K$PP6P\7M(K!:,<<P
MK,\Z<&]X21$5.K^01+9:664 S_J%X;"^<(+7L'+Z*\0[DFI/03LB5H0Q>-]D
M33D>!JU*K735'^$U8HUECHJP0K]XW+*/1 M7\!B&9&;.UVAA*@D"<11;2(S
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M8G-2S.["JQF5CE.DG1+G'=RW@V>._4NI]2Y%G&%#VE514C<X1E/9%S6' ,5
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MRUQ_MABT]VF 5)#Y;;FCV9VHR)UYSDX@XB.NDF[6Z4Z<[W&Y)O_"J;$B#*0
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MKO8EEAV$^DJG"G_A9RV9>0AGAIMB$Q>U+R#2%Y#E[L1_'"7&$GA0CQEB>*W
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MJJHV*%:C&]^F807:0KMC^+ITZMNP+"X..H2P;-SVIV"58(?[O>"S^',M)%H
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MK/1 Y]Q&7$1$<#3T+EJC!AR;?9 7^#T(YM>GP^_\F%+A5&'#^I?R$U/4/F3
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MV+TKIBTBF,,W6\5^'IT3M9J"6#/AQ0(L)GH!M*96R'/:.;OHBT[K["W:)=P
M@/M9UXT4JA8.WB3]?CX&MZSGL7,8BC7# 8 .+[4&*CQUQI"2(:>H]<JJA''!
MP<5,='D(!&</]W93N@]-9"K]/LC\*&PI6N25O[![1U>K?;C-+JSOQO"?/?S
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M+?L;%1F7.[VBC:#$0DWM7)SK5M;C6"F/N8Z;4]ND9))N-*QN_G?>(=S,I;O
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MY,_A;SR]!?_?N,IB KJN1$45U&^_;A_M?H4??CS]=/#^_P=02P,$%     @
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MA?<#-H$81VP$%[S(9GAU$@ )VH(]K=MI#(_C<>79\GJZO97=IO#3-%G0H_8
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MHO 3\0,H!A)GQT%0J-Y1P.]B/1J<K)$I/9D-Q2OD"7F2Y5HJ&<VR@J[V $V
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M#]TDK'TSB2S81+0CKL6-,?8^4\I&H# 6>ZKG"_;;6S;+-*: F[L/;0+VTTS
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M&( 9')F2I,8GM"%4AE-C<Y.0(CE7! Y'EN+4)QUP49D?I>@\ME@^0=F>Z\'
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M9<O?.LZKI6W>"(^TO54W%'(+4V:GS3GC+$T:);4^RU<T9HJ8-7IODRA!]10
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M2[)'R>#DB8).O&TU;"2LY!4,[9ZN:+#&'A;GQFF*[)8M:%[.[\9 EJ8%87$
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M:+)X\D$\GFABC%V3.<)9 #H'D9M>26)+$@DP[QAR/.A/P-\3?>"SY-3%'/B
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M8-U^]AK:/8T> !,!_2[[3QJFH23+.TMH6:Y;W^"E_N6>_P)02P,$%     @
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M!4MHLAVK,B*(K]0%>/.!;&VQK$CN",]Z*[PFR 77&D$D;+,*D)> M :H(LX
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M,3$N:'1M4$L! A0#%     @ CH'K6/A,YH7:.P  ;/T  !
M ( !I.<  &0X,#<P.3%D97@T,2YH=&U02P$"% ,4    " ".@>M8VNU5#$$0
M  # 1P  $               @ &L(P$ 9#@P-S Y,61E>#4Q+FAT;5!+ 0(4
M Q0    ( (Z!ZUCFJ*[&/0,  % +   1              "  1LT 0!I9'EA
M+3(P,C0P-S Y+GAS9%!+ 0(4 Q0    ( (Z!ZUC=(5C>>@8  +I&   5
M          "  8<W 0!I9'EA+3(P,C0P-S Y7VQA8BYX;6Q02P$"% ,4
M" ".@>M8"LS+><($  !"+   %0              @ $T/@$ :61Y82TR,#(T
B,#<P.5]P<F4N>&UL4$L%!@     '  < NP$  "E# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d807091d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="idya-20240709.xsd" xlink:type="simple"/>
    <context id="duration_2024-07-09_to_2024-07-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2024-07-09</startDate>
            <endDate>2024-07-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-296">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-07-09_to_2024-07-09"
      id="Hidden_dei_EntityCentralIndexKey">0001676725</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-307">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-308">2024-07-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-309">IDEAYA Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-310">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-311">001-38915</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-312">47-4268251</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-313">7000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-314">Suite 350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-315">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-316">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-317">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-318">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-319">443-6209</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-320">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-321">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-322">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-323">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-324">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-325">IDYA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-326">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-07-09_to_2024-07-09" id="ixv-327">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
